(RTTNews) - Myelodysplastic syndrome, which refers to a group of blood disorders, affects an estimated 60,000 people in the U.S. The abnormal or malignant precursor cells in the bone marrow ...

Imetelstat improves eight- and 24-week transfusion independence in patients with low-risk myelodysplastic syndrome, according to topline study results. The phase 3 IMerge trial met its main goal, ...

Geron Corporation GERN announced positive top-line data from the phase III IMerge study evaluating its lead pipeline candidate, imetelstat in lower risk myelodysplastic syndromes (MDS) patients who ...

For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs), the competitive telomerase ...

The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, ...

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial. Patients with ...

We highlighted Geron Corporation GERN in this space in June 2018, citing the positive clinical trial results achieved so far by imetelstat, the company’s therapeutic candidate for myelofibrosis and ...

Shares of Geron Corporation GERN were up 29.8% after the company published data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory ...

Imetelstat (Rytelo; Geron) significantly improved and sustained health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), with benefits linked directly to the drug ...

Title: Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents ...

More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic syndromes ...

Imetelstat and ruxolitinib pharmacokinetic profiles in the combination study were similar to previous monotherapy studies. These early results show potential for the tolerability of the combination of ...